Garrison Financial Corp raised its stake in shares of Medtronic PLC (NYSE:MDT) by 3.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,208 shares of the medical technology company’s stock after purchasing an additional 1,265 shares during the quarter. Medtronic makes up about 1.7% of Garrison Financial Corp’s holdings, making the stock its 27th biggest holding. Garrison Financial Corp’s holdings in Medtronic were worth $2,971,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Parkside Financial Bank & Trust boosted its holdings in shares of Medtronic by 22.4% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,146 shares of the medical technology company’s stock valued at $102,000 after buying an additional 210 shares in the last quarter. BDO Wealth Advisors LLC bought a new stake in shares of Medtronic during the 2nd quarter valued at $103,000. Motco boosted its holdings in shares of Medtronic by 8.7% during the 2nd quarter. Motco now owns 1,239 shares of the medical technology company’s stock valued at $110,000 after buying an additional 99 shares in the last quarter. Farmers National Bank bought a new stake in shares of Medtronic during the 1st quarter valued at $121,000. Finally, Israel Discount Bank of New York bought a new stake in shares of Medtronic during the 1st quarter valued at $117,000. 81.86% of the stock is currently owned by institutional investors and hedge funds.

In other Medtronic news, CEO Omar Ishrak sold 140,407 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $81.63, for a total value of $11,461,423.41. Following the completion of the transaction, the chief executive officer now owns 668,503 shares of the company’s stock, valued at approximately $54,569,899.89. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Bryan C. Hanson sold 16,000 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $78.03, for a total value of $1,248,480.00. The disclosure for this sale can be found here. In the last three months, insiders sold 172,407 shares of company stock valued at $13,974,223. 0.31% of the stock is owned by insiders.

Shares of Medtronic PLC (MDT) traded up $0.50 during trading hours on Monday, reaching $81.07. The company’s stock had a trading volume of 4,106,400 shares, compared to its average volume of 4,958,920. Medtronic PLC has a fifty-two week low of $69.35 and a fifty-two week high of $89.72. The company has a current ratio of 2.40, a quick ratio of 2.05 and a debt-to-equity ratio of 0.50. The stock has a market cap of $109,728.08, a price-to-earnings ratio of 17.47, a price-to-earnings-growth ratio of 2.24 and a beta of 1.00.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.08. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The business had revenue of $7.05 billion during the quarter, compared to analyst estimates of $7.05 billion. During the same quarter in the previous year, the firm earned $1.12 EPS. Medtronic’s revenue was down 4.0% on a year-over-year basis. sell-side analysts anticipate that Medtronic PLC will post 4.77 EPS for the current year.

MDT has been the topic of a number of research reports. Royal Bank Of Canada restated a “buy” rating and set a $90.00 target price on shares of Medtronic in a report on Monday, August 21st. Oppenheimer restated a “buy” rating and set a $92.00 target price on shares of Medtronic in a report on Tuesday, August 22nd. Cowen set a $95.00 target price on shares of Medtronic and gave the company a “buy” rating in a report on Tuesday, August 22nd. BMO Capital Markets restated an “outperform” rating and set a $92.00 target price (down previously from $94.00) on shares of Medtronic in a report on Wednesday, August 23rd. Finally, Barclays dropped their target price on shares of Medtronic from $94.00 to $92.00 and set an “overweight” rating on the stock in a report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $88.02.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/medtronic-plc-mdt-shares-bought-by-garrison-financial-corp/1757530.html.

Medtronic Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.